Literature DB >> 22887948

Genistein-induced mitotic arrest of gastric cancer cells by downregulating KIF20A, a proteomics study.

Guang-Rong Yan1, Fei-Yan Zou, Bian-Li Dang, Ye Zhang, Guangchuang Yu, Xiao Liu, Qing-Yu He.   

Abstract

Genistein exerts its anticarcinogenic effects by inducing G2/M arrest and apoptosis of cancer cells. However, the precise molecular mechanism of action of genistein has not been completely elucidated. In this study, we used quantitative proteomics to identify the genistein-induced protein alterations in gastric cancer cells and investigate the molecular mechanism responsible for the anti-cancer actions of genistein. Total 86 proteins were identified to be regulated by genistein, most of which were clustered into the regulation of cell division and G2/M transition, consistent with the anti-cancer effect of genistein. Many proteins including kinesin family proteins, TPX2, CDCA8, and CIT were identified for the first time to be regulated by genistein. Interestingly, five kinesin family proteins including KIF11, KIF20A, KIF22, KIF23, and CENPF were found to be simultaneously downregulated by genistein. Significantly decreased KIF20A was selected for further functional studies. The silencing of KIF20A inhibited cell viability and induced G2/M arrest, similar to the effects of genistein treatment in gastric cancer. And the silencing of KIF20A also increased cancer cell sensitivity to genistein inhibition, whereas overexpression of KIF20A markedly attenuated genistein-induced cell viability inhibition and G2/M arrest. These observations suggested that KIF20A played an important role in anti-cancer actions of genistein, and thus may be a potential molecular target for drug intervention of gastric cancer.
© 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22887948     DOI: 10.1002/pmic.201100652

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  35 in total

Review 1.  Genistein and cancer: current status, challenges, and future directions.

Authors:  Carmela Spagnuolo; Gian Luigi Russo; Ilkay Erdogan Orhan; Solomon Habtemariam; Maria Daglia; Antoni Sureda; Seyed Fazel Nabavi; Kasi Pandima Devi; Monica Rosa Loizzo; Rosa Tundis; Seyed Mohammad Nabavi
Journal:  Adv Nutr       Date:  2015-07-15       Impact factor: 8.701

2.  Identification of prognostic markers of high grade prostate cancer through an integrated bioinformatics approach.

Authors:  Hai Huang; Qin Zhang; Chen Ye; Jian-Min Lv; Xi Liu; Lu Chen; Hao Wu; Lei Yin; Xin-Gang Cui; Dan-Feng Xu; Wen-Hui Liu
Journal:  J Cancer Res Clin Oncol       Date:  2017-08-28       Impact factor: 4.553

3.  Functional analysis of KIF20A, a potential immunotherapeutic target for glioma.

Authors:  Katsuya Saito; Shigeki Ohta; Yutaka Kawakami; Kazunari Yoshida; Masahiro Toda
Journal:  J Neurooncol       Date:  2017-01-09       Impact factor: 4.130

Review 4.  Genistein: Therapeutic and Preventive Effects, Mechanisms, and Clinical Application in Digestive Tract Tumor.

Authors:  Shenglin Hou
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-29       Impact factor: 2.650

Review 5.  Genistein as a regulator of signaling pathways and microRNAs in different types of cancers.

Authors:  Zeeshan Javed; Khushbukhat Khan; Jesús Herrera-Bravo; Sajid Naeem; Muhammad Javed Iqbal; Haleema Sadia; Qamar Raza Qadri; Shahid Raza; Asma Irshad; Ali Akbar; Željko Reiner; Ahmed Al-Harrasi; Ahmed Al-Rawahi; Dinara Satmbekova; Monica Butnariu; Iulia Cristina Bagiu; Radu Vasile Bagiu; Javad Sharifi-Rad
Journal:  Cancer Cell Int       Date:  2021-07-21       Impact factor: 6.429

6.  XI-006 induces potent p53-independent apoptosis in Ewing sarcoma.

Authors:  Kathleen I Pishas; Alaknanda Adwal; Susan J Neuhaus; Mark T Clayer; Gelareh Farshid; Alexander H Staudacher; David F Callen
Journal:  Sci Rep       Date:  2015-06-22       Impact factor: 4.379

Review 7.  Genistein: An Integrative Overview of Its Mode of Action, Pharmacological Properties, and Health Benefits.

Authors:  Javad Sharifi-Rad; Cristina Quispe; Muhammad Imran; Abdur Rauf; Muhammad Nadeem; Tanweer Aslam Gondal; Bashir Ahmad; Muhammad Atif; Mohammad S Mubarak; Oksana Sytar; Oxana Mihailovna Zhilina; Ekaterina Robertovna Garsiya; Antonella Smeriglio; Domenico Trombetta; Daniel Gabriel Pons; Miquel Martorell; Susana M Cardoso; Ahmad Faizal Abdull Razis; Usman Sunusi; Ramla Muhammad Kamal; Lia Sanda Rotariu; Monica Butnariu; Anca Oana Docea; Daniela Calina
Journal:  Oxid Med Cell Longev       Date:  2021-07-19       Impact factor: 6.543

8.  Protective effects of andrographolide analogue AL-1 on ROS-induced RIN-mβ cell death by inducing ROS generation.

Authors:  Guang-Rong Yan; Hui-Hua Zhou; Yang Wang; Yin Zhong; Zi-Lu Tan; Yuqiang Wang; Qing-Yu He
Journal:  PLoS One       Date:  2013-06-04       Impact factor: 3.240

9.  Establishment of a new OSCC cell line derived from OLK and identification of malignant transformation-related proteins by differential proteomics approach.

Authors:  Yan Dong; Qun Zhao; Xiaoyan Ma; Guowu Ma; Caiyun Liu; Zhuwen Chen; Liyuan Yu; Xuefeng Liu; Yanguang Zhang; Shujuan Shao; Jing Xiao; Jia Li; Weimin Zhang; Ming Fu; Lijia Dong; Xiandong Yang; Xu Guo; Liyan Xue; Fei Fang; Qimin Zhan; Lihua Zhang
Journal:  Sci Rep       Date:  2015-08-03       Impact factor: 4.379

10.  Epigenetic silencing of ITGA2 by MiR-373 promotes cell migration in breast cancer.

Authors:  Wen Ding; Xiao-Lu Fan; Xuan Xu; Jin-Zhou Huang; Song-Hui Xu; Qian Geng; Rong Li; De Chen; Guang-Rong Yan
Journal:  PLoS One       Date:  2015-08-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.